Literature DB >> 1634047

Dynamic changes in HIV-1 quasispecies from azidothymidine (AZT)-treated patients.

J Wahlberg1, J Albert, J Lundeberg, S Cox, B Wahren, M Uhlén.   

Abstract

The emergence of azidothymidine (AZT)-resistant human immunodeficiency virus (HIV) variants in clinical samples was studied by a direct genomic sequencing method. Sequential lymphocyte samples from four patients, who had been treated with AZT for up to 27 months, were shown to gradually accumulate multiple nucleotide changes, some of which are known to be associated with AZT resistance. Several samples were shown to contain mixtures of wild-type and mutated genomes, indicating gradual rather than sudden changes in the HIV-1 quasispecies. These results demonstrate for the first time that automated solid-phase DNA sequencing is a rapid and useful tool for investigation of antiviral drug resistance and suggest that DNA sequencing may be important in routine clinical diagnostics in the future.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1634047     DOI: 10.1096/fasebj.6.10.1634047

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  12 in total

1.  Use of automated sequencing of polymerase chain reaction-generated amplicons to identify three types of cholera toxin subunit B in Vibrio cholerae O1 strains.

Authors:  O Olsvik; J Wahlberg; B Petterson; M Uhlén; T Popovic; I K Wachsmuth; P I Fields
Journal:  J Clin Microbiol       Date:  1993-01       Impact factor: 5.948

2.  Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.

Authors:  S Palmer; J Harmenberg; S Cox
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  High rate of recombination throughout the human immunodeficiency virus type 1 genome.

Authors:  A E Jetzt; H Yu; G J Klarmann; Y Ron; B D Preston; J P Dougherty
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

5.  Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.

Authors:  J Albert; J Wahlberg; J Lundeberg; S Cox; E Sandström; B Wahren; M Uhlén
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

Review 6.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs.

Authors:  J E Fitzgibbon; A E Farnham; S J Sperber; H Kim; D T Dubin
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid-phase sequencing.

Authors:  J Odeberg; Z Yun; A Sönnerborg; M Uhlén; J Lundeberg
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

Review 9.  Magnetic separation techniques in diagnostic microbiology.

Authors:  O Olsvik; T Popovic; E Skjerve; K S Cudjoe; E Hornes; J Ugelstad; M Uhlén
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

10.  Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats.

Authors:  W K Greene; J Meers; G del Fierro; P R Carnegie; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.